Trial · NCT05050955
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | ALAD | 1 year post-transplant | Diagnostic performance characteristics (sensitivity, specificity, PPV, NPV) of AlloSure Lung to detect acute lung allograft dysfunction (ALAD). |
| Secondary | Chronic lung allograft dysfunction | 3 years post-transplant | Clinical diagnostic performance characteristics (sensitivity, specificity, PPV and NPV) of AlloSure Lung to detect chronic lung allograft dysfunction. |
| Secondary | Acute cellular rejection | 3 years post-transplant | Clinical diagnostic performance characteristics (sensitivity, specificity, PPV and NPV) of AlloSure Lung to detect acute cellular rejection (ACR). |
| Secondary | Antibody mediated rejection | 3 years post-transplant | Clinical diagnostic performance characteristics (sensitivity, specificity, PPV and NPV) of AlloSure Lung to detect antibody mediated rejection (AMR). |
| Secondary | Acute infection | 3 years post-transplant | Clinical diagnostic performance characteristics (sensitivity, specificity, PPV and NPV) of AlloSure Lung to detect acute infection. |
| Secondary | Subject Variability | 3 years post-transplant | Define within-subject and between-subject variability of AlloSure Lung in clinically stable patients in order to establish reference change value RCV. |
| Secondary | ALAD vs. Stability | 3 years post-transplant | Evaluate the diagnostic performance characteristics of utilizing RCV to distinguish ALAD vs. Stability |
| Secondary | Biopsy-proven rejections | 3 years post-transplant | The proportion of biopsy-proven rejections with elevated AlloSure Lung versus those without elevated AlloSure-Lung. |
| Secondary | AlloSure Lung Results | 3 years post-transplant | The proportion of AlloSure Lung results obtained as surveillance or for-cause, that the physicians felt influenced their decisions around management of patients. |
| Secondary | ALAD Free survival | 3 years post-transplant | ALAD free survival in lung transplant recipients who received AlloSure Lung as part of post-transplant surveillance. |
| Secondary | AlloSure Levels | 3 years post-transplant | Evaluate AlloSure levels 30-90 days prior to acute rejection. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05050955/registered